Automatic Website Traffic RSS

Neurogenic Orthostatic Hypotension

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they ... read more

Theravance to Present Analyses of Ampreloxetine and Neurogenic Orthostatic Hypotension at the 2025 International MSA Congress

Ampreloxetine, an investigational, once-daily norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple ... read more

Theravance Biopharma to Present New Ampreloxetine Analyses in Neurogenic Orthostatic Hypotension (nOH) at the 77th Annual Meeting of the American Academy of Neurology

Ampreloxetine, an investigational, once-daily norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple ... read more

Chelsea Therapeutics Announces New Data from Northera Phase III Program in Neurogenic Orthostatic Hypotension

Chelsea Therapeutics International, Ltd. CHTP announced that new data from Phase III trials in symptomatic neurogenic orthostatic hypotension demonstrating the activity and tolerability of NORTHERA™ ... read more

Chelsea Therapeutics Announces Northera Poster Presentations and Symposium on Neurogenic Orthostatic Hypotension at MDS 15th International Congress of Parkinson's Disease and ...

CHARLOTTE, N.C., May 2, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that two posters describing the clinical benefit of NORTHERA™ (droxidopa) have been ... read more

Renal Function and Sodium Metabolism in Idiopathic Orthostatic Hypotension

PATIENTS with idiopathic orthostatic hypotension demonstrate various hemodynamic abnormalities in response to standing. Reflex peripheral vasoconstriction fails to occur normally, 1 venous return to ... read more

Chelsea Therapeutics Confirms Plan to File Northera NDA for the Treatment of Neurogenic Orthostatic Hypotension in Third Quarter 2011 and Intent to Pursue Supplemental Falls ...

April 18, 2011, 8:16 AM EDT / Source: GlobeNewswire CHARLOTTE, N.C., April 18, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) reaffirms NORTHERA ™ (droxidopa) new drug ... read more

PET Explains Orthostatic Hypotension in Parkinson's Disease

NEW YORK (MedscapeWire) Apr 26 — A positron emission tomography (PET) study of 18 F fluorodopamine uptake, described in the April 23 issue of Neurology, sheds new light on orthostatic hypotension and ... read more

Cause of postural tachycardia syndrome discovered

Boston, MA - The neuropathic postural tachycardia syndrome (PTS), a chronic form of orthostatic intolerance that primarily affects young women, is due to partial sympathetic denervation, especially in ... read more

First Neurogenic Orthostatic Hypotension Drug Launched

First Neurogenic Orthostatic Hypotension Drug OK’d in Two Decades Lundbeck announced the availability of Northera (droxidopa) capsules for the treatment of orthostatic dizziness and lightheadedness in ... read more